Share

Low Risk Thyroid Cancer: Rating the Risks

ENDO_2022_4C While certain thyroid cancer patients who have very small nodules well-located within the thyroid can be counseled rather than operated on, other patients might fare better undergoing surgery. At ENDO 2022, experts weigh in and debate when to operate and when to watch in patients with low-risk thyroid cancer in the session “Endocrine Debate: Low...
Share

All About Adrenal: Analyzing Two Years of Research

ENDO_2022_4C When the ENDO 2022 session “Clinical Year in Review: All Things Adrenal” gets underway, Gary Hammer, MD, PhD, will treat attendees to the series of advances that have been made in adrenal science and clinical practice over the last two years, from adrenal homeostasis, glucocorticoid biology, and adrenal insufficiency to Cushing’s, tumors, pheochromocytoma, and more....
Share

Gender-Affirming Care: Bridging the Gap

ENDO_2022_4C As transgender medical care becomes unfairly politicized, presentations such as ENDO 2022’s Meet the Professor session “Beginner’s Guide to Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults” are more essential than ever. Attendees will be shown a variety of best practices in providing affirming care to transgender and gender diverse adults.   On the...
Share

Does Thyroid Hormone Replacement Undertreatment Worsen Hospital Outcomes?

Study finds undertreatment can lead to longer stay and higher readmission rates. Undertreatment with thyroid hormone replacement can put patients with hypothyroidism at risk for worse hospital outcomes, including longer length of stay and higher rates of readmission, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism. Hypothyroidism, or...
Share

NEW ENDO 2022 Experiences You Can’t Miss!

april 2022 cover Our first hybrid ENDO 2022 includes enhanced experiences for attendees from in-person networking events to new opportunities for endocrine scientists that you surely will not want to miss. Our team is working hard to make sure this ENDO is the best one yet and is dedicated to revamping the experience to include in-person features to...
Share

Data Presented at ENDO 2021 Shows Promise for Treating Cushing’s Syndrome

A poster presented at ENDO 2021 appears to show promise for a new treatment aimed at patients with Cushing’s syndrome. The poster, presented by Strongbridge Biopharma, plc, a global commercial-stage biopharmaceutical company, announced that detailed results from the previously reported Phase 3 LOGICS study of RECORLEV® (levoketoconazole) in patients with endogenous Cushing’s syndrome were presented...
Show More